TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00812201

Intervention type: DEVICE
Intervention: No intervention is used. Collection of signals only.
Description: Device received per standard of care.
Study: NCT03162510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel /nab-Paclitaxel
Description: 150 mg/m2 IVD 30 min bi-weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
Study: NCT05282576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NPF Group
Description: Participants allocated to the experimental group completed until discharged, neurophysiological facilitation(NPF) techniques in addition to conventional physiotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Critical ill patients was applied their conventional physiotherapy which includes chest physiotherapy and mobilization until discharged
Study: NCT02662153

Intervention type: OTHER
Intervention: Observation only
Description: No intervention.

Intervention type: OTHER
Intervention: Observation only
Description: No intervention.

Intervention type: OTHER
Intervention: Observation only
Description: No intervention.
Study: NCT00944814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS with zinc
Description: Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LNS without zinc
Description: LNS containing no zinc
Study: NCT04376684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otilimab
Description: Otilimab will be administered once via IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otilimab
Description: Otilimab will be administered once via IV route.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: All participants will receive standard of care as per institutional protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: All participants will receive standard of care as per institutional protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: All participants will receive standard of care as per institutional protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: All participants will receive standard of care as per institutional protocol.
Study: NCT02784119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temporary porto-caval shunt
Description: temporary porto-caval shunt
Study: NCT03835494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
Description: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
Description: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
Study: NCT01797601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin
Description: 160 U of insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Insulin dilution medium without insulin
Study: NCT00064844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy for alcohol and smoking cessation
Description: Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavior Therapy for alcohol and smoking cessation
Description: Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
Study: NCT02232386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
Study: NCT00064844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm CQ nicotine patch
Description: Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicoderm CQ nicotine patch
Description: Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
Study: NCT03928210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
Study: NCT02520297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Description: Drug
Study: NCT02466971

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Undergo brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo brachytherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo conventional RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo conventional RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given IV
Study: NCT00991419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AZD4694
Description: \[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
Study: NCT04229927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPDO-1603
Description: Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug
Study: NCT03887455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: 10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: 10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Biweekly (once every 2 weeks) administered as i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: 720 milligram (mg) weekly administered as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: 360 mg weekly administered as subcutaneous injection.
Study: NCT06403306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Sulfate (Viskostat; Ultradent, Utah, USA)
Description: Widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The metal-protein complex, formed due to contact with blood, creates a mechanical plug; thus, hemostasis occurs without clot formation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)
Description: Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (Waterlase MD, Biolase, USA)
Description: Alternative technique introduced to clinical practice in recent years to provide hemostasis in vital pulp treatment is the usage of lasers in various wavelengths. Using lasers in pulpotomy provides many advantages such as tissue vaporization and coagulation, maintenance of a blood-free working field due to its property to close small blood vessels, minimal clot formation, and sterilization of the wound surface. Furthermore, laser systems were reported to induce cellular biostimulation. Er,Cr:YSGG lasers which belong to the Erbium laser family are the laser systems with the highest absorption rate by water, having a wavelength of 2780 nm. Besides, Erbium lasers manifest bactericidal effects.
Study: NCT03440736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life-style intervention
Description: A structured program to guide weight loss and increased physical activity
Study: NCT00230802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticipatory dose increase of levothyroxine
Description: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticipatory dose increase of levothyroxine
Description: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Description: patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Description: patients will increase levothyroxine by 3 extra tablets of their current dose per week.
Study: NCT02871713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral Quadratus lumborum block with 0.5% ropivacaine
Description: Bilateral Quadratus lumborum block with 0.5% ropivacaine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral Quadratus lumborum block with 0.5% ropivacaine
Description: Bilateral Quadratus lumborum block with 0.5% ropivacaine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine with 100 mcg morphine
Description: Intrathecal Morphine with 100 mcg morphine
Study: NCT00064844

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gum
Description: Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum - Nicorette®
Description: Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
Study: NCT03839745

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Cigarette
Description: E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
Study: NCT04229927

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPDO-1603
Description: Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug
Study: NCT01385449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene catheter
Description: interscalene catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene block
Description: interscalene block
Study: NCT03839745

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Cigarette
Description: E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Cigarette
Description: E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
Study: NCT03867305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOBIDERM
Description: Use of a MOBIDERM mobilizing band after total knee prosthesis
Study: NCT00547092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: 25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
Study: NCT02573857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265
Description: Oral suspension from bulk powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265
Description: Oral suspension from bulk powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: Oral suspension from powder in a bottle
Study: NCT01489592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcuma longa
Description: oral administration of 6 grams of curcumin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcuma longa
Description: oral administration of 6 grams of curcumin
Study: NCT04480437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mp-BUS data collection
Description: Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.
Study: NCT03548337

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: 13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: 13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
Study: NCT01698801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
Study: NCT02871713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrathecal Morphine with 100 mcg morphine
Description: Intrathecal Morphine with 100 mcg morphine
Study: NCT03428581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALND with ARM +/- LVB
Description: Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALND
Description: Prospective and retrospective subjects undergoing an ALND.
Study: NCT03785249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: MRTX849 will be administered orally once or twice daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: MRTX849 will be administered orally once or twice daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: MRTX849 will be administered orally once or twice daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: MRTX849 will be administered orally once or twice daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: MRTX849 will be administered orally once or twice daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: MRTX849 will be administered orally once or twice daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: MRTX849 will be administered orally once or twice daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: MRTX849 will be administered orally once or twice daily in a continuous regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: MRTX849 will be administered orally once or twice daily in a continuous regimen
Study: NCT01698801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
Study: NCT01183897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Description: This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops.
Study: NCT03785249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered as an intravenous infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
Study: NCT01777256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 50 mg
Description: GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.